MEC Plus

How I Treat Advanced Head and Neck Cancer
How I Treat Advanced Head and Neck Cancer
A. Dimitrios Colevas, MD
Castration Resistant Prostate Cancer: What is the optimal approach?
Castration Resistant Prostate Cancer: What is the optimal approach?
Sandy Srinivas, MD
State of the Art: Hormone-sensitive Prostate Cancer
State of the Art: Hormone-sensitive Prostate Cancer
Tanya Dorff, MD
AML: Current Status and Future Directions
AML: Current Status and Future Directions
George Yaghmour, MD, FACP
Updates in Treatment of Lymphoma
Updates in Treatment of Lymphoma
Joseph Tuscano, MD
MDS: State of the Art
MDS: State of the Art
Paul Koller, MD
Keynote Lecture – The Future of Targeted Therapy in Lung Cancer
Keynote Lecture – The Future of Targeted Therapy in Lung Cancer
Pasi A. Janne, MD, PhD
Updates in Treatment of Early Stage and Locally Advanced NSCLC
Updates in Treatment of Early Stage and Locally Advanced NSCLC
Erminia Massarelli, MD, PhD, MS
Advances in Small Cell Lung Cancer and Mesothelioma
Advances in Small Cell Lung Cancer and Mesothelioma
Jorge Nieva, MD
Updates in Targeted Therapy for NSCLC
Updates in Targeted Therapy for NSCLC
Jonathan W. Riess, MD, MS
Updates in Immunotherapy for Lung Cancer: Integration of Predictive Biomarkers
Updates in Immunotherapy for Lung Cancer: Integration of Predictive Biomarkers
David Gandara, MD
Esophageal and Gastric Cancer: New Developments
Esophageal and Gastric Cancer: New Developments
George Fisher, MD, PhD
Pancreatic Cancer: Emerging Strategies
Pancreatic Cancer: Emerging Strategies
Vincent Chung, MD, FACP
Progress in CAR-T Cell Therapies
Progress in CAR-T Cell Therapies
Stephen Forman, MD
Management of Immune Related Adverse Events
Management of Immune Related Adverse Events
Alicia Rigby, RN, MSN, FNP, AOCNP
Immunotherapy in Cancer: Next Generation Biomarkers
Immunotherapy in Cancer: Next Generation Biomarkers
Peter Lee, MD
How I treat Stage III NSCLC
How I treat Stage III NSCLC
Karen Kelly, MD
PK and PD Considerations in Early Phase Clinical Trials
PK and PD Considerations in Early Phase Clinical Trials
Tim Synold, PharmD
Statistical Considerations in Early Phase Clinical Trial Design in the Era of Targeted Therapy and Immunotherapy
Statistical Considerations in Early Phase Clinical Trial Design in the Era of Targeted Therapy and Immunotherapy
Mark Krailo, PhD
Mesothelioma and Thymoma – Limited and Advanced Stage
Mesothelioma and Thymoma – Limited and Advanced Stage
Matthew Gubens, MD
Small Cell Lung Cancer
Small Cell Lung Cancer
Millie Das, MD
Other Immunotherapy Targets & Agents- Advanced NSCLC
Other Immunotherapy Targets & Agents- Advanced NSCLC
Nathaniel Myall, MD, MS
PD-1/PD-L1 Directed Immunotherapy for Advanced NSCLC
PD-1/PD-L1 Directed Immunotherapy for Advanced NSCLC
Jonathan W. Riess, MD, MS
Other Oncogene-Driven Cancers
Other Oncogene-Driven Cancers
Collin Blakely, MD, PhD
EGFR Mutated Lung Cancer - Advanced Stage
EGFR Mutated Lung Cancer - Advanced Stage
David Gandara, MD
ALK, ROS1, and BRAF Positive Lung Cancer
ALK, ROS1, and BRAF Positive Lung Cancer
Joel Neal, MD, PhD
Tumor Biology, Pathology, Novel Diagnostics
Tumor Biology, Pathology, Novel Diagnostics
Tianhong “Tina” Li, MD, PhD
Stage III NSCLC – Surgical/Combined Modality
Stage III NSCLC – Surgical/Combined Modality
Leah Backhus, MD
Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy
Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy
Primo Lara, Jr, MD